In older adults with T1D, less daytime hypoglycemia was the biggest predictor of improvements in IAH in a 6-month study.

Glucagon-like peptide-1 agonist drugs have been surging in popularity, and manufacturers are scurrying to keep up with demand. Overall, the GLP-1 market is expected to experience annual growth ...

SAB-142 is a human alternative to rabbit anti-thymocyte globulin (ATG). SAB-142’s mechanism of action is analogous to that of rabbit ATG, which has been clinically validated in multiple clinical ...

(Yicai) May 21 -- Chinese regulators have given the green light to Eli Lilly’s diabetes drug tirzepatide, the US ...

CKM syndrome, a cluster of conditions that may lead to heart disease, may affect 90% of U.S. adults. Doctors explain ...

Coordinating appointments, treatments often a slog in our segmented health care system, but there are ways to rein it in ...

SAB Biotherapeutics, Inc. (SABS) announced on Tuesday that the FDA has granted clearance for an investigational new drug application ...

COUR Pharmaceuticals, a clinical-stage biotechnology company focused on the development of ?rst-in-class, disease-modifying therapies designed to induce antigen-speci?c tolerance for immune-mediated ...

Answered by Dr. Howard E. Lewine M.D. Chief Medical Editor, Harvard Health Publishing · 40 years of experience · USA There is ...

Nestle’s Vital Pursuit brand’s initial lineup of 12 items will include frozen bowls with whole grains or protein pasta, sandwich melts and pizzas.

HealthToday, a leading platform dedicated to enhancing global health through evidence-based content, is thrilled to announce ...

Eli Lilly (NYSE:LLY) has secured China approval for its blockbuster drug tirzepatide for use in treating diabetes.